Literature DB >> 29152338

Crystal structure of methyl (Z)-2-[(Z)-3-methyl-2-({(E)-1-[(R*)-4-methyl-cyclo-hex-3-en-1-yl]ethyl-idene}hydrazinyl-idene)-4-oxo-thia-zolidin-5-yl-idene]acetate.

Mourad Fawzi1, Aziz Auhmani1, Moulay Youssef Ait Itto1, Abdelkhalek Riahi2, Sylviane Chevreux2, El Mostafa Ketatni3.   

Abstract

The new title 4-thia-zolidinone derivative, C16H21N3O3S, was obtained from the cyclization reaction of 4-methyl-3-thio-semicarbazone and dimethyl acetyl-enedi-carboxyl-ate (DMAD). The cyclo-hexyl-idene ring has an envelope conformation with the stereogenic centre C atom as the flap. Its mean plane makes a dihedral angle of 56.23 (9)° with the thia-zolidine ring mean plane. In the crystal, mol-ecules are linked by C-H⋯O hydrogen bonds forming chains propagating in the [001] direction. Within the chains there are offset π-π inter-actions between the thia-zolidine rings of inversion-related mol-ecules [centroid-centroid distance = 3.703 (1) Å]. The chains are linked by further C-H⋯O hydrogen bonds, forming slabs parallel to the ac plane.

Entities:  

Keywords:  C—H⋯O hydrogen bonds; crystal structure: hydrazine: thia­zol­idinone; offset π–π inter­actions

Year:  2017        PMID: 29152338      PMCID: PMC5683478          DOI: 10.1107/S2056989017014311

Source DB:  PubMed          Journal:  Acta Crystallogr E Crystallogr Commun


Chemical context

It has been reported that thia­zolidinones exhibit anti­bacterial (Mayekar & Mulwad, 2008 ▸), anti­fungal (Omar et al. 2010 ▸), anti­convulsant (Bhat et al., 2008 ▸), anti­tubercular (Babaoglu et al., 2003 ▸), anti-inflammatory (Vigorita et al. 2003 ▸), anti­histaminic (Agrawal et al., 2000 ▸), cardiovascular (Suzuki et al., 1999 ▸) and anti-HIV (Rawal et al., 2005 ▸) activities. With the aim of preparing new thia­zolidinone derivatives, we report herein on the synthesis (Fig. 1 ▸) and crystal structure of the title compound 3, from 4-methyl-3-thio­semicarbazone 1. Treatment of 1 with dimethyl acetyl­enedi­carboxyl­ate 2 in boiling ethanol for 1 h, afforded the thia­zolidin-4-one 3 in 90% yield. Its structure has also been fully characterized by NMR spectroscopy while its relative stereochemistry was determined based mainly on the synthetic pathway and implied by the X-ray diffraction analysis.
Figure 1

Reaction scheme for the synthesis of title compound 3.

Structural commentary

The title compound 3, is built up from an thia­zolidinone ring linked to cyclo­hexyl­idene-hydrazone and meth­oxy-oxo­ethyl­idene units (Fig. 2 ▸). The compound crystallizes in the centrosymmetric space group P , and the stereogenic centre at C8 was assigned as having an R configuration. As expected, the thia­zolidine ring and all the atoms attached to it (plane A = S1/C4/C5/N1/C6/N2/N3/O1/C3/C14) are roughly coplanar with an r.m.s. deviation of 0.036 Å. Its mean plane makes a dihedral angle of 56.0 (1)° with the mean plane of the cyclo­hexyl­idene ring (C8-C13). The meth­oxy­carbonyl group (C1/O2/O3/C2) is also twisted slightly with respect to plane A, their mean planes being inclined to one another by 11.2 (2)°. The six-membered cyclo­hexyl­idene ring has an envelope conformation with atom C8 as the flap: puckering parameters are Q = 0.494 (2) Å, θ = 129.8 (2)° and φ = 180.8 (3)°. The C7=N3 and N2=C6 bond lengths are 1.282 (2) and 1.278 (2) Å, respectively, consistent with C=N double bonding. The C6—N2—N3—C7, C4—C3—C2—O3 and C3—C2—O3—C1 torsion angles are 175.5 (2), −172.4 (2) and 172.5 (2)°, respectively.
Figure 2

The mol­ecular structure of the title compound 3, with the atom labelling. Displacement ellipsoids are drawn at the 30% probability level.

Supra­molecular features

In the crystal, mol­ecules are linked C3—H3⋯O3i hydrogen bonds, forming chains propagating along [001]; see Table 1 ▸ and Fig. 3 ▸. Within the chains there are weak offset π–π stacking inter­actions between inversion-related thia­zole rings [see Fig. 3 ▸; Cg1Cg1(−x + 1, −y + 1, −z) = 3.703 (1) Å,where Cg1 is the centroid of the S1/N1/C4–C6 ring, inter­planar distance = 3.468 (1) Å, slippage = 1.298 Å]. The chains are linked by further C—H⋯O hydrogen bonds, forming slabs lying parallel to the ac plane (Table 1 ▸, Figs. 4 ▸ and 5 ▸).
Table 1

Hydrogen-bond geometry (Å, °)

D—H⋯A D—HH⋯A DA D—H⋯A
C3—H3⋯O3i 0.952.593.4133 (19)146
C1—H1C⋯O1ii 0.982.513.208 (2)128
C14—H14A⋯O2iii 0.982.453.252 (2)139
C14—H14B⋯O2iv 0.982.483.409 (2)159
C15—H15A⋯O3iv 0.982.553.351 (2)139

Symmetry codes: (i) ; (ii) ; (iii) ; (iv) .

Figure 3

Partial crystal packing for title compound 3, showing the C3—H3⋯O3i hydrogen bonds and the offset π–π inter­actions between inversion-related mol­ecules, forming chains in the [001] direction (dashed lines; only atom H3 has been included).

Figure 4

Packing and hydrogen-bonding inter­actions of the title compound viewed along the b axis. For clarity, only the H atoms involved in the hydrogen bonds (dashed lines) inter­actions have been included.

Figure 5

Packing and hydrogen-bonding inter­actions of the title compound, viewed along the a axis. For clarity, only the H atoms involved in hydrogen bonding (dashed lines) have been included.

Database survey

A search of the Cambridge Structural Database (CSD, Version 5.38, last update May 2017; Groom et al., 2016 ▸) using a thia­zolidone substituted by meth­oxy-oxo­ethyll­idene and methyl­hydrazone as the main skeleton gave eight hits. The most relevant structures are methyl (2-{[1-(4-hy­droxy­phen­yl)ethyl­idene]hydrazono}-4-oxo-3-phenyl-1,3-thia­zolidin-5-yl­idene)acetate (AGOMUG; Mohamed, Mague et al., 2013 ▸), methyl (2-{[1-(4-methyl­phen­yl)ethyl­idene]hydrazono}-4-oxo-3-phenyl-1,3-thia­zolidin-5-yl­idene)acetate (NIPPAF; Mague et al., 2013 ▸) and dimethyl 2-[(4-{N-[5-(2-meth­oxy-2-oxo­ethyl­idene)-4-oxo-3-phenyl-1,3-thia­zolidin-2-yl­idene]ethane­hydrazono­yl}phen­yl)amino]­but-2-enedioate (RIMDIC; Mohamed, Akkurt et al., 2013 ▸). A comparison of the main C—N, N—N, C—S bond lengths in the title compound and the structures extracted from the CSD shows a good correlation. The C=N—N=C torsion angles indicate that in each case the four atoms are nearly planar, viz. 175.5 (2)° in the title compound, 172.1 (2)° in AGOMUG, −178.9 (2) and −165.5 (2)° in NIPPAF and −167.4 (5)° in RIMDIC.

Synthesis and crystallization

To a solution of 4-methyl-3-thio­semicarbazone (200 mg, 1.33 mmol) in ethanol (15 ml) was added dimethyl acetyl­enedi­carboxyl­ate (DMAD) (0.24 ml, 1.66 mmol). The mixture was stirred under reflux for 1 h, leading to the corresponding thia­zolidinone. After cooling, the mixture was extracted with ethyl acetate (3 × 20 ml). The organic layer was washed with water, dried on anhydrous Na2SO4 and then evaporated under reduced pressure. The obtained residue was chromatographed on a silica gel column using hexane as eluent, to give compound 3 (yield 404 mg, 90%). Yellow prismatic crystals were obtained from a petroleum ether solution, by slow evaporation of the solvent at room temperature.

Refinement

Crystal data, data collection and structure refinement details are summarized in Table 2 ▸. The C-bound H atoms were placed in calculated positions with C—H = 0.95–1.00 Å, and refined in the riding-model approximation with U iso(H) = 1.5U eq(C-meth­yl) and 1.2U eq(C) for other H atoms.
Table 2

Experimental details

Crystal data
Chemical formulaC16H21N3O3S
M r 335.42
Crystal system, space groupTriclinic, P
Temperature (K)100
a, b, c (Å)9.0982 (2), 9.9556 (3), 10.5071 (3)
α, β, γ (°)66.772 (1), 74.572 (1), 77.706 (1)
V3)836.76 (4)
Z 2
Radiation typeCu Kα
μ (mm−1)1.88
Crystal size (mm)0.39 × 0.28 × 0.20
 
Data collection
DiffractometerD8 Venture CMOS area detector
Absorption correctionNumerical (SADABS; Bruker, 2012)
T min, T max 0.733, 0.919
No. of measured, independent and observed [I > 2σ(I)] reflections30681, 3405, 3195
R int 0.035
(sin θ/λ)max−1)0.625
 
Refinement
R[F 2 > 2σ(F 2)], wR(F 2), S 0.038, 0.102, 1.06
No. of reflections3405
No. of parameters212
H-atom treatmentH-atom parameters constrained
Δρmax, Δρmin (e Å−3)0.42, −0.46

Computer programs: APEX2 and SAINT (Bruker, 2012 ▸), SHELXS2014 (Sheldrick, 2008 ▸), SHELXL2014 (Sheldrick, 2015 ▸), ORTEP-3 for Windows (Farrugia, 2012 ▸), DIAMOND (Brandenburg & Putz, 2012 ▸), PLATON (Spek, 2009 ▸) and publCIF (Westrip, 2010 ▸).

Crystal structure: contains datablock(s) I, Global. DOI: 10.1107/S2056989017014311/su5396sup1.cif Structure factors: contains datablock(s) I. DOI: 10.1107/S2056989017014311/su5396Isup2.hkl Click here for additional data file. Supporting information file. DOI: 10.1107/S2056989017014311/su5396Isup3.cml CCDC reference: 1577993 Additional supporting information: crystallographic information; 3D view; checkCIF report
C16H21N3O3SZ = 2
Mr = 335.42F(000) = 356
Triclinic, P1Dx = 1.331 Mg m3
a = 9.0982 (2) ÅCu Kα radiation, λ = 1.54178 Å
b = 9.9556 (3) ÅCell parameters from 9903 reflections
c = 10.5071 (3) Åθ = 4.9–74.5°
α = 66.772 (1)°µ = 1.88 mm1
β = 74.572 (1)°T = 100 K
γ = 77.706 (1)°Prismatic, yellow
V = 836.76 (4) Å30.39 × 0.28 × 0.20 mm
D8 Venture CMOS area detector diffractometer3195 reflections with I > 2σ(I)
Radiation source: microsourceRint = 0.035
φ and ω scansθmax = 74.5°, θmin = 4.7°
Absorption correction: numerical (SADABS; Bruker, 2012)h = −11→11
Tmin = 0.733, Tmax = 0.919k = −12→12
30681 measured reflectionsl = −12→13
3405 independent reflections
Refinement on F2Primary atom site location: structure-invariant direct methods
Least-squares matrix: fullSecondary atom site location: difference Fourier map
R[F2 > 2σ(F2)] = 0.038Hydrogen site location: inferred from neighbouring sites
wR(F2) = 0.102H-atom parameters constrained
S = 1.06w = 1/[σ2(Fo2) + (0.048P)2 + 0.6482P] where P = (Fo2 + 2Fc2)/3
3405 reflections(Δ/σ)max = 0.016
212 parametersΔρmax = 0.42 e Å3
0 restraintsΔρmin = −0.46 e Å3
Geometry. All esds (except the esd in the dihedral angle between two l.s. planes) are estimated using the full covariance matrix. The cell esds are taken into account individually in the estimation of esds in distances, angles and torsion angles; correlations between esds in cell parameters are only used when they are defined by crystal symmetry. An approximate (isotropic) treatment of cell esds is used for estimating esds involving l.s. planes.
xyzUiso*/Ueq
S10.40715 (4)0.68958 (4)−0.11410 (4)0.01854 (12)
O10.80122 (13)0.54559 (13)−0.29654 (13)0.0255 (3)
O20.21903 (13)0.59108 (14)−0.22869 (13)0.0262 (3)
O30.31331 (13)0.45665 (12)−0.36926 (12)0.0219 (3)
N10.70665 (15)0.66298 (14)−0.13721 (14)0.0192 (3)
N20.56362 (16)0.77397 (15)0.02334 (15)0.0222 (3)
N30.40773 (15)0.81672 (15)0.07586 (15)0.0215 (3)
C10.15960 (19)0.4245 (2)−0.3520 (2)0.0267 (4)
H1A0.12670.3563−0.25540.040*
H1B0.15940.3793−0.41960.040*
H1C0.08870.5160−0.36920.040*
C20.32641 (18)0.53614 (17)−0.29626 (17)0.0194 (3)
C30.48814 (18)0.54559 (17)−0.30630 (17)0.0205 (3)
H30.56570.5084−0.36900.025*
C40.52821 (17)0.60574 (17)−0.22856 (17)0.0184 (3)
C50.69402 (18)0.59946 (17)−0.22780 (17)0.0193 (3)
C60.56930 (18)0.71493 (17)−0.06627 (17)0.0189 (3)
C70.38679 (18)0.86854 (17)0.17420 (17)0.0201 (3)
C80.22330 (18)0.90988 (17)0.23980 (17)0.0200 (3)
H80.22021.00190.25790.024*
C90.1056 (2)0.9394 (2)0.14898 (19)0.0281 (4)
H9A0.13371.02030.05790.034*
H9B0.10690.85020.12850.034*
C10−0.0542 (2)0.9808 (2)0.22322 (18)0.0263 (4)
H10−0.12691.04670.17020.032*
C11−0.0941 (2)0.92015 (19)0.3727 (2)0.0259 (4)
C120.01418 (19)0.83015 (18)0.45599 (18)0.0235 (3)
H12A−0.02950.73750.51880.028*
H12B0.02360.88050.51750.028*
C130.1742 (2)0.7892 (2)0.38279 (19)0.0289 (4)
H13A0.17780.69620.36810.035*
H13B0.24740.77250.44400.035*
C140.85481 (18)0.66081 (19)−0.10627 (19)0.0243 (4)
H14A0.93790.6357−0.17750.036*
H14B0.86250.5871−0.01240.036*
H14C0.86330.7581−0.10820.036*
C150.51144 (19)0.88538 (19)0.23429 (18)0.0239 (3)
H15A0.52900.79660.31620.036*
H15B0.48030.97090.26380.036*
H15C0.60640.89960.16210.036*
C16−0.2564 (2)0.9523 (2)0.4458 (2)0.0317 (4)
H16A−0.31700.87630.45730.048*
H16B−0.30161.04880.38880.048*
H16C−0.25640.95260.53900.048*
U11U22U33U12U13U23
S10.01467 (19)0.0227 (2)0.0196 (2)−0.00267 (14)−0.00178 (14)−0.00991 (15)
O10.0160 (5)0.0333 (6)0.0293 (7)−0.0041 (5)0.0009 (5)−0.0163 (5)
O20.0173 (6)0.0360 (7)0.0308 (7)−0.0030 (5)−0.0017 (5)−0.0198 (5)
O30.0184 (5)0.0264 (6)0.0251 (6)−0.0044 (4)−0.0042 (4)−0.0130 (5)
N10.0152 (6)0.0218 (6)0.0207 (7)−0.0042 (5)−0.0028 (5)−0.0073 (5)
N20.0195 (7)0.0258 (7)0.0221 (7)−0.0038 (5)−0.0033 (5)−0.0097 (6)
N30.0195 (7)0.0250 (7)0.0217 (7)−0.0035 (5)−0.0025 (5)−0.0110 (6)
C10.0207 (8)0.0324 (9)0.0324 (10)−0.0078 (7)−0.0060 (7)−0.0144 (8)
C20.0196 (8)0.0206 (7)0.0179 (8)−0.0039 (6)−0.0031 (6)−0.0063 (6)
C30.0170 (7)0.0240 (8)0.0206 (8)−0.0040 (6)−0.0001 (6)−0.0097 (6)
C40.0149 (7)0.0197 (7)0.0185 (8)−0.0035 (6)−0.0002 (6)−0.0060 (6)
C50.0167 (7)0.0206 (7)0.0191 (8)−0.0048 (6)−0.0011 (6)−0.0057 (6)
C60.0172 (7)0.0190 (7)0.0187 (8)−0.0036 (6)−0.0030 (6)−0.0045 (6)
C70.0228 (8)0.0196 (7)0.0182 (8)−0.0043 (6)−0.0052 (6)−0.0055 (6)
C80.0224 (8)0.0216 (7)0.0184 (8)−0.0029 (6)−0.0050 (6)−0.0092 (6)
C90.0258 (9)0.0407 (10)0.0236 (9)0.0015 (7)−0.0088 (7)−0.0180 (8)
C100.0229 (8)0.0360 (9)0.0225 (9)−0.0026 (7)−0.0083 (7)−0.0111 (7)
C110.0227 (8)0.0282 (8)0.0349 (10)−0.0060 (7)−0.0035 (7)−0.0197 (8)
C120.0267 (8)0.0240 (8)0.0210 (8)−0.0058 (6)−0.0024 (6)−0.0096 (7)
C130.0260 (9)0.0283 (9)0.0239 (9)0.0004 (7)−0.0038 (7)−0.0032 (7)
C140.0165 (8)0.0305 (9)0.0277 (9)−0.0028 (6)−0.0062 (6)−0.0114 (7)
C150.0232 (8)0.0284 (8)0.0247 (8)−0.0027 (6)−0.0074 (7)−0.0130 (7)
C160.0241 (9)0.0427 (10)0.0343 (10)−0.0031 (7)−0.0046 (7)−0.0215 (9)
S1—C41.7469 (16)C8—H81.0000
S1—C61.7736 (16)C9—C101.512 (2)
O1—C51.212 (2)C9—H9A0.9900
O2—C21.211 (2)C9—H9B0.9900
O3—C21.3403 (19)C10—C111.416 (3)
O3—C11.4495 (19)C10—H100.9500
N1—C51.372 (2)C11—C121.415 (2)
N1—C61.385 (2)C11—C161.504 (2)
N1—C141.462 (2)C12—C131.509 (2)
N2—C61.278 (2)C12—H12A0.9900
N2—N31.4174 (19)C12—H12B0.9900
N3—C71.282 (2)C13—H13A0.9900
C1—H1A0.9800C13—H13B0.9900
C1—H1B0.9800C14—H14A0.9800
C1—H1C0.9800C14—H14B0.9800
C2—C31.467 (2)C14—H14C0.9800
C3—C41.340 (2)C15—H15A0.9800
C3—H30.9500C15—H15B0.9800
C4—C51.499 (2)C15—H15C0.9800
C7—C151.503 (2)C16—H16A0.9800
C7—C81.508 (2)C16—H16B0.9800
C8—C91.527 (2)C16—H16C0.9800
C8—C131.532 (2)
C4—S1—C690.05 (7)C10—C9—H9B109.4
C2—O3—C1115.77 (13)C8—C9—H9B109.4
C5—N1—C6115.69 (13)H9A—C9—H9B108.0
C5—N1—C14121.75 (13)C11—C10—C9119.25 (15)
C6—N1—C14122.23 (13)C11—C10—H10120.4
C6—N2—N3108.81 (13)C9—C10—H10120.4
C7—N3—N2114.54 (13)C12—C11—C10122.07 (16)
O3—C1—H1A109.5C12—C11—C16118.75 (16)
O3—C1—H1B109.5C10—C11—C16119.18 (16)
H1A—C1—H1B109.5C11—C12—C13118.89 (15)
O3—C1—H1C109.5C11—C12—H12A107.6
H1A—C1—H1C109.5C13—C12—H12A107.6
H1B—C1—H1C109.5C11—C12—H12B107.6
O2—C2—O3124.53 (14)C13—C12—H12B107.6
O2—C2—C3124.24 (15)H12A—C12—H12B107.0
O3—C2—C3111.22 (13)C12—C13—C8111.68 (14)
C4—C3—C2121.12 (14)C12—C13—H13A109.3
C4—C3—H3119.4C8—C13—H13A109.3
C2—C3—H3119.4C12—C13—H13B109.3
C3—C4—C5120.42 (14)C8—C13—H13B109.3
C3—C4—S1127.81 (12)H13A—C13—H13B107.9
C5—C4—S1111.70 (11)N1—C14—H14A109.5
O1—C5—N1124.96 (14)N1—C14—H14B109.5
O1—C5—C4125.02 (15)H14A—C14—H14B109.5
N1—C5—C4110.01 (13)N1—C14—H14C109.5
N2—C6—N1122.47 (14)H14A—C14—H14C109.5
N2—C6—S1125.00 (12)H14B—C14—H14C109.5
N1—C6—S1112.53 (11)C7—C15—H15A109.5
N3—C7—C15125.43 (15)C7—C15—H15B109.5
N3—C7—C8117.47 (14)H15A—C15—H15B109.5
C15—C7—C8117.04 (14)C7—C15—H15C109.5
C7—C8—C9115.06 (13)H15A—C15—H15C109.5
C7—C8—C13109.94 (13)H15B—C15—H15C109.5
C9—C8—C13108.72 (14)C11—C16—H16A109.5
C7—C8—H8107.6C11—C16—H16B109.5
C9—C8—H8107.6H16A—C16—H16B109.5
C13—C8—H8107.6C11—C16—H16C109.5
C10—C9—C8111.08 (14)H16A—C16—H16C109.5
C10—C9—H9A109.4H16B—C16—H16C109.5
C8—C9—H9A109.4
D—H···AD—HH···AD···AD—H···A
C3—H3···O3i0.952.593.4133 (19)146
C1—H1C···O1ii0.982.513.208 (2)128
C14—H14A···O2iii0.982.453.252 (2)139
C14—H14B···O2iv0.982.483.409 (2)159
C15—H15A···O3iv0.982.553.351 (2)139
  12 in total

1.  2-(Aryl)-3-furan-2-ylmethyl-thiazolidin-4-ones as selective HIV-RT inhibitors.

Authors:  Ravindra K Rawal; Yenamandra S Prabhakar; S B Katti; E De Clercq
Journal:  Bioorg Med Chem       Date:  2005-09-28       Impact factor: 3.641

2.  Novel 4-thiazolidinone derivatives as potential antifungal and antibacterial drugs.

Authors:  Kouatli Omar; Athina Geronikaki; Panagiotis Zoumpoulakis; Charalabos Camoutsis; Marina Soković; Ana Cirić; Jasmina Glamoclija
Journal:  Bioorg Med Chem       Date:  2009-10-27       Impact factor: 3.641

3.  Chiral 3,3'-(1,2-ethanediyl)-bis[2-(3,4-dimethoxyphenyl)-4-thiazolidinones] with anti-inflammatory activity. Part 11: evaluation of COX-2 selectivity and modelling.

Authors:  M G Vigorita; R Ottanà; F Monforte; R Maccari; M T Monforte; A Trovato; M F Taviano; N Miceli; G De Luca; S Alcaro; F Ortuso
Journal:  Bioorg Med Chem       Date:  2003-03-20       Impact factor: 3.641

4.  Effects of CP-060S, a novel cardioprotective drug, on cardiac function and myocardial oxygen consumption.

Authors:  Y Suzuki; M Akima; K Tamura
Journal:  Gen Pharmacol       Date:  1999-01

5.  Novel inhibitors of an emerging target in Mycobacterium tuberculosis; substituted thiazolidinones as inhibitors of dTDP-rhamnose synthesis.

Authors:  Kerim Babaoglu; Mark A Page; Victoria C Jones; Michael R McNeil; Changjiang Dong; James H Naismith; Richard E Lee
Journal:  Bioorg Med Chem Lett       Date:  2003-10-06       Impact factor: 2.823

6.  Dimethyl (2Z)-2-[4-((1Z)-1-{2-[(2Z,5Z)-5-(2-meth-oxy-2-oxo-ethyl-idene)-4-oxo-3-phenyl-1,3-thia-zolidin-2-yl-idene]hydra-zin-1-yl-idene}eth-yl)anilino]but-2-ene-dio-ate.

Authors:  Shaaban K Mohamed; Mehmet Akkurt; Joel T Mague; Alaa A Hassan; Mustafa R Albayati
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2013-11-30

7.  Crystal structure refinement with SHELXL.

Authors:  George M Sheldrick
Journal:  Acta Crystallogr C Struct Chem       Date:  2015-01-01       Impact factor: 1.172

8.  Structure validation in chemical crystallography.

Authors:  Anthony L Spek
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2009-01-20

9.  Methyl 2-((2Z,5Z)-2-{(E)-2-[1-(4-hy-droxy-phen-yl)ethyl-idene]hydrazin-1-yl-idene}-4-oxo-3-phenyl-1,3-thia-zolidin-5-yl-idene)acetate.

Authors:  Shaaban K Mohamed; Joel T Mague; Mehmet Akkurt; Alaa A Hassan; Mustafa R Albayati
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2013-09-18

10.  The Cambridge Structural Database.

Authors:  Colin R Groom; Ian J Bruno; Matthew P Lightfoot; Suzanna C Ward
Journal:  Acta Crystallogr B Struct Sci Cryst Eng Mater       Date:  2016-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.